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The replacement of a deficient gene by its normal copy has been the basis of the treatment 
envisioned for gene therapy of inherited disorders. With improving and rapidly advancing 
insight, showing that the products of genes and their regulation also play a crucial role in 
many other diseases, including acquired diseases, gene therapy now holds promises and 
expectations for the treatment of numerous disorders that range from cancer to infectious 
diseases like AIDS. The principle of gene therapy has therefore been reconsidered and 
refocused as bearing relevance not only to replacing a potentially deficient gene but also, and 
more importantly, to influencing the physiology and signal transduction in the cell by over-
expressing or down-regulating one or several genes, for example those expressing membrane 
receptors. Down-regulation of a gene can be achieved by the transfer of short antisense 
oligonucleotides (ODNs) into cells or by intracellular delivery of the more recently 
developed small interfering RNA (siRNA). In addition, a gene can be expressed by 
translocating plasmid DNA into cells containing the sequence for a gene of interest under the 
influence of a promotor. 
The methods for delivering nucleic acids (ODNs, siRNA or plasmid DNA) to the cells 
are divided into two groups, i.e., viral and non-viral methods. Viral vectors were developed 
first and take advantage of the natural ability of a virus to penetrate into cells and use their 
machinery for the production of viral proteins. Although very efficient in vitro and in vivo, 
viral vectors may pose problems in terms of safety for the use as therapeutic drugs because 
of their immunogenicity and in some cases the potential risk of insertion of the gene into the 
host genome that can lead to the development of cancer as some recent clinical studies have 
shown [1]. Non-viral vectors that comprise cationic lipids and cationic polymers are thought 
to be safer in vivo because they are immunologically inert. They can also accommodate a 
greater variety of cargo and are not limited to coding sequences of nucleic acid as viral 
vectors but can deliver directly antisense ODNs and siRNA. These vectors are also easier to 
produce and can be readily chemically modified for the purpose of improving therapeutic 
applications. The efficiency of these vectors, however, is lower than that of viral vectors and 
has until now precluded their extensive use for in vivo therapeutic applications. Therefore a 
better understanding of the parameters that govern transfection efficiency of non-viral 
vectors will be crucial for the development of in vivo applications. 
The aim of this thesis was to characterize the mechanisms of transfection mediated by 
lipoplexes prepared from different cationic lipids and to study potential applications of these 
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vectors for gene therapy. Two cationic lipid systems are used in this thesis: the SAINT-2 
cationic lipid system used in combination with dioleoylphosphatidylethanolamine (DOPE) 
for the delivery of antisense ODNs (Chapters 3 and 4) and a cationic lipid system that 
consists of pH sensitive sugar-based gemini surfactants (Chapters 5 and 6). Chapter 2 
presents a review on the use of cationic lipids for gene delivery. The biophysical parameters 
important for the formation of the complexes, interaction with the cell membrane and further 
intracellular delivery of nucleic acids in the cells are discussed in this chapter. It emphasizes 
the importance of structural properties of the lipoplexes in each step of the transfection 
process and discusses the potential role played by a helper lipid, like DOPE. Furthermore 
endocytosis of lipoplexes, mediating cellular entry, and the mechanism of endosomal 
disruption are considered in this chapter. Finally, the important role of non-bilayer phases of 
lipoplexes (inverted hexagonal, hexagonal and cubic micellar phases) in endosomal 
disruption is discussed. 
Poly(ethylene glycol) (PEG)-lipid analogues are used in gene delivery to stabilize 
lipoplexes, thereby preventing interaction with serum components and non-target cells and 
thus promoting a longer blood circulation time of such (PEG-) coated lipoplexes. In chapter 
3, the effect of different PEG-lipid analogues on lipoplex formation with ODNs, the 
structural phases of PEGylated lipoplexes and the efficiency of intracellular delivery of 
ODNs is investigated. The non-exchangeable DSPE-PEG is compared to ceramide-PEG 
analogues of variable chain lengths with correlated variable exchangeable properties. It is 
shown that DSPE-PEG prevents the nuclear translocation of ODNs by preventing their 
release from the endosomal compartment. Because of its higher exchangeability, the short 
ceramide-C8-PEG analogue did not preclude as extensively as DSPE-PEG the release and 
translocation of ODNs to the nucleus. Finally, cryo-EM and SAXS measurements showed 
that DSPE-PEG stabilizes the lamellar phase of lipoplexes. 
In previous work, it was demonstrated that SAINT-2/DOPE-ODN lipoplexes are 
efficient carriers in the delivery of antisense ODNs to neuronal cell lines, leading to an 
effective and functional down-regulation of neuronal membrane receptors [2]. Accordingly, 
we considered the option to exploit the principle of this approach in designing a non-
invasive antisense therapy to the brain, and aimed at the construction of means and devices 
for lipoplexes to cross the blood-brain barrier (BBB). The purpose of the studies described in 
chapter 4 of this thesis was to set up an experimental in vitro model for the BBB in our 
laboratory, to study the interaction of SAINT-2/DOPE-ODN lipoplexes with this BBB 
model, and to investigate lipoplex transport across the cell monolayer. The first part of the 
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chapter describes the successful introduction of this BBB model, including its morphological 
and structural characterization.. Adsorption-mediated transcytosis is a well characterized 
mechanism for cationic entities to cross cell monolayers, but despite the cationic nature of 
the lipoplexes, transcytosis and subsequent secretion at the opposite side of the cells was not 
observed. Furthermore we show in this chapter that coupling of a model protein BSA 
precluded the capacity of SAINT-2/DOPE cationic liposomes to form complexes with ODNs. 
Therefore, coupling strategies for the purpose of triggering receptor-mediated transcytosis, a 
mechanism that has been characterized for transferrin and its receptor, will require 
improvement in order to eventually accomplish successful translocation of lipoplexes across 
endothelial cell layers. 
In chapter 5 mechanistic features and the transfection efficiency of different pH 
sensitive sugar-based gemini surfactants were investigated, both in vitro and in vivo. These 
sugar-based gemini surfactants contain two protonatable amino moieties in the head group, 
the charge of which depends on the pH. Thus, the extent to which the two amino moieties 
are charged will influence the relative size of the head group of the cationic lipid, which is 
reflected by a pH-dependent phase behavior [3,4]. Out of the five compounds examined, two 
surfactants with an ethylene oxide spacer, GS1 and GS2, were found to effectively transfect 
cells in vitro with a relatively low level of toxicity. Both compounds were shown to adopt at 
physiological pH a lamellar phase and to display a good colloidal stability in salt and serum. 
In vivo transfection experiments showed that because of this relative stability at 
physiological pH, both compounds were capable of avoiding ‘preliminary capture’ as large 
clustered complexes in the lung capillaries, as inferred from the absence of transfection in 
the lungs, evidenced by bioluminescence imaging. 
Finally, in chapter 6 a study is presented on the potential mechanism of transfection, 
mediated by the two pH sensitive gemini surfactants, GS1 and GS2. Of particular interest, 
these studies revealed that the gemini lipoplexes undergo a lamellar-to-non-inverted micellar 
(HI) phase transition with decreasing pH as occurs in the endosomal compartment. This 
observation is novel, since it contrasts the common observation reported for numerous other 
lipoplexes, which display a lamellar-to-hexagonal HII transition. A lipid mixing assay and 
plasmid DNA release studies demonstrated that these lipoplexes disrupt model membranes 
particularly at acidic rather than at neutral or basic pH. Furthermore, the presence of PS in 
the target membrane was necessary for disruption to occur. From these studies, we conclude 
that the gemini-based lipoplexes undergo at mild acidic pH a lamellar- to- normal (non-
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inverted) hexagonal HI phase, and that next to complexes that display an HII phase, also the 
HI phase can lead to membrane disruption, endosomal release and subsequent transfection. 
Discussion and perspectives 
We show in this thesis how PEG-lipid analogues, although capable of prolonging the 
circulation time of lipoplexes and preventing interaction with blood components and cells, 
can also negatively affect the effectiveness of intracellular delivery of lipoplex cargo. We 
also show that lipoplexes, formed from pH sensitive sugar-based gemini surfactants mimic 
some of the properties of the PEGylated complexes by similarly displaying a good stability 
at neutral pH, while they are able to disrupt (endosomal) membranes at acidic pH and 
transfect cells. Experiments to determine the circulation time of these lipoplexes in vivo and 
their biodistribution, as compared to PEGylated lipoplexes, would be of interest in order to 
evaluate whether these compounds would be an interesting alternative to the use of 
PEGylated lipids. In addition to maintaining a lamellar phase, PEG-lipids also confer stealth 
property by providing a hydrophilic coating to the lipoplexes and creating a steric barrier. 
With the gemini surfactants this hydrophilic coating is provided by the reduced sugar in the 
head group. For further development, the steric barrier properties of other gemini surfactants 
with longer sugar chains could be tested for their interaction with blood components. 
For targeting purposes, such sugar-based gemini surfactants could be functionalized at 
the level of the head group, involving the coupling of a targeting ligand. The possibility of 
such coupling and the capacity to form efficient lipoplexes should be studied. Evidently, the 
potential spectrum for applications of such targeting strategies would be numerous, ranging 
from the targeting of tumors for cancer gene therapy to the exploitation of receptor-mediated 
transcytosis for strategies of blood-brain barrier crossing. 
On a more fundamental basis, concerning the mechanism of transfection, studies of the 
intracellular fate of gemini lipoplexes could bring more insight into the intracellular 
trafficking of lipoplexes in general. Since the transfection properties of such sugar-based 
gemini surfactants, in contrast to other surfactant systems, is dependent on the pH, caveolae-
mediated endocytosis of these lipoplexes might be induced, for example by further 
manipulating their size, which may serve as a trigger for such an event [5]. Importantly, 
since this mechanism of internalization likely avoids exposure of lipoplexes to a mild acidic 
pH environment, this pathway should not lead to transfection. Accordingly, such 
experiments would allow to sort out whether such a caveolae-mediated pathway is relevant 
to endocytosis of lipoplexes and whether this pathway could be instrumental in transcytosis 
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in endothelial cell crossing, given that this cell type is particularly enriched in caveolae on its 
surface.  
To increase the potential of cationic lipid systems as vectors for the use in gene 
therapy, precise insight is needed into the different barriers involved in eventual expression 
of the delivered gene. In this context, some very recent observations indicate that nucleic 
acid release via endosomes to the cytosol occurs as efficiently with lipoplexes as with 
adenovirus particles [6]. This would suggest that intracellular delivery of nucleic acid is not 
the limiting step in transfection but that other parameters are involved. Studies on the effect 
of cationic lipids on the condensation of genes and their ensuing stability in the cytosol, in 
conjunction with an effect on transcription efficiency, may provide more insight into issues 
such as why viral vectors can be more efficient in transfection, in spite of delivering a 
substantially lower number of gene copies into the nucleus. 
On a more general basis, gene therapy using cationic lipids represents 8.3 % of the 
gene therapy clinical trials worldwide (updated from January 2006 at 
www.wiley.co.uk/wileychi/genmed/clinical/) against 49 % for adenovirus and retrovirus 
systems together. This emphasizes that more insight is needed to address questions as to why 
cationic lipid-mediated transfection is less efficient than virus-mediated transfection, with 
approaches as described above and throughout this thesis. Moreover, in addition to 
developing new cationic lipid vectors, it would be necessary to broaden and diversify 
applications for existing vectors. Testing different cell types and different cargos, and 
exploiting different ways of administration will allow further development of these vectors 
for in vivo applications of gene therapy. 
The resemblance of non-viral vectors with traditional drugs, in the way that they can 
be developed or produced, is their greatest advantage. A specialization of cationic lipids, to a 
disease or to an administration route, might bring more realism in the development of these 
vectors as effective drugs for gene therapy. For example, in case of the pH sensitive sugar-
based gemini surfactants used in this thesis, a non-anticipated observation in the in vivo 
experiments might trigger a new range of applications for these compounds. Thus, in these 
studies, we observed in the mouth of the animal, injected with gemini lipoplexes, expression 
of the reporter gene, suggesting efficient transfection. This probably resulted from ingestion 
of the gemini lipoplexes by the mice, which also might have led to some transfection of the 
gastrointestinal tract. Further experiments with oral delivery of these lipoplexes to verify this 
hypothesis will be needed but could well lead to novel applications in oral gene therapy. For 
instance, oral gene therapy can be considered for the treatment of recurrent or refractory oral 
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cancers, like the oral squamous cell carcinoma [7]. Oral gene therapy could also be an 
alternative in the treatment of type 1 diabetes, such treatment would aim at delegating the 
production and secretion of insulin to the small intestine [8,9]. These approaches represent 
interesting potential therapeutic applications for sugar-based gemini surfactants. 
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